In direct compression lines producing immediate-release tablets, Perlalux Duplex Pharma Grade API is pre-screened through a 0.500 mm stainless-steel sieve and dry-blended with microcrystalline cellulose, croscarmellose sodium and magnesium stearate in a bin blender at 6–12 rpm for 15–25 min. The active substance loading is set between 5.0% w/w and 45.0% w/w depending on label claim and diluent compaction characteristics; below 5.0% w/w, blend uniformity must be verified by stratified sampling and assay at 3 depth points in accordance with USP <905>. Compression runs on a rotary tablet press equipped with 12–30 stations and pre-compression rollers at 8–20 kN pre-compression and 15–60 kN main compression; ejection force is monitored below 1,500 N to avoid lamination caused by excessive die-wall friction. Moisture content of the Perlalux fraction is held below 1.5% before compression, and if LOD exceeds 2.0%, vacuum drying at 40–50°C is required to prevent picking and sticking. Tablets are characterised for hardness (50–120 N), friability per USP <1216>, disintegration time per USP <701> and dissolution by USP <711> Apparatus 2 at 50–75 rpm in 900 mL of specified medium. The unit operation must comply with 21 CFR 211.84 for incoming API identity, 21 CFR 211.110 for sampling and in-process control, ICH Q3D for elemental impurities and ICH M7 where mutagenic impurities are relevant. Terminal finished products are immediate-release uncoated tablets, film-coated tablets and bilayer tablets where the active layer contains Perlalux at the same loading range.

Hard Gelatin Capsule Filling at Low-Dose Drug Loading

Hard gelatin capsule filling at low-dose drug loading combines Perlalux Duplex Pharma Grade API with a free-flowing diluent mixture after geometric pre-mixing in a low-shear cube blender. The active content is typically 0.5% w/w to 20.0% w/w; when the nominal dose falls below 1 mg per capsule, a direct compression-grade lactose or mannitol carrier is first premixed with colloidal silicon dioxide at 0.2–0.5% w/w to reduce segregation. Filling is carried out on an automatic capsule filling machine with dosator or tamping-pin dosing stations set to fill weight tolerances of ±3% of target; empty capsule shells are size 3 to 00 depending on fill volume and formulation bulk density, which is controlled to 0.45–0.65 g/mL. Blend uniformity testing follows USP <905>, and stratified sampling across 10 locations is required at the start, middle and end of the hopper to detect sieve segregation. Dissolution testing for the filled capsules uses USP <711> Apparatus 1 at 100 rpm or Apparatus 2 at 50 rpm with 900 mL of dissolution medium; disintegration is confirmed by USP <2040> or USP <701> depending on the pharmacopoeial monograph. Compliance is anchored to 21 CFR 211.80 for bulk pharmaceutical substance storage, 21 CFR 211.94 for drug product containers and ICH Q3C for residual solvent limits when granulation or coating solvents are used upstream. Finished products are immediate-release hard capsules for oral administration, printed or clear, in blister or HDPE packs.

Because direct compression of high-dose Perlalux formulations may produce powders with insufficient flow and low bulk density, dry granulation by roller compaction is used to densify the blend before tablet compression or capsule filling. Perlalux is pre-blended with microcrystalline cellulose, lactose monohydrate and crospovidone at drug loadings of 30% w/w to 75% w/w, then passed through a roller compactor with roll pressure 4–12 kN/cm, roll gap 1.5–3.0 mm and roll speed 2–10 rpm. The resulting ribbons are milled using an oscillating granulator fitted with 0.8–1.25 mm screens; the granule fraction is blended with extragranular disintegrant and lubricant to a final lubricant content not exceeding 1.0% w/w magnesium stearate, which prevents dissolution slowdown caused by over-lubrication. Ribbon density is monitored at 1.10–1.35 g/cm³ and granule particle size distribution is measured by USP <786>, with the fraction below 75 µm limited to <20% to avoid re-aggregation. Powder flow is assessed using USP <1174>; compressibility index and Hausner ratio are calculated from bulk and tapped density per USP <616>, with values below 25% and 1.34 respectively considered acceptable for high-speed compression. The dry granulation process must satisfy 21 CFR 211.110 for in-process monitoring, ICH Q3D for elemental impurities from metal contact surfaces, and ISO 8573-1:2010 for compressed air purity when pneumatic transfer is used. Finished product types are immediate-release tablets, dispersible tablets and hard capsules manufactured from the resulting granules.

What Limits Batch Size When Perlalux Is Processed by Wet Granulation?

Wet granulation becomes the rate-limiting unit operation when Perlalux batches exceed 300 kg because high-shear mixing, binder distribution, and drying endpoint heterogeneity influence downstream tabletability. In high-shear granulators with impeller speeds of 100–400 rpm and chopper speeds of 1,500–3,000 rpm, Perlalux is granulated at drug loadings of 10% w/w to 60% w/w using purified water or a 3–5% w/w povidone binder solution. The wet mass endpoint is determined by impeller torque and visual consistency; because published thermal degradation data for this specific Perlalux formulation is limited, dryer inlet and product temperature limits are derived from forced degradation studies under ICH Q1A, and granulate moisture after fluid-bed drying at inlet temperatures of 50–70°C is targeted to 1.5–3.5% LOD. Milling follows through a 1.0–2.0 mm screen; oversized granules above 1.5 mm are returned to the mill until the distribution meets USP <786>. Extragranular disintegrant is added at 2–5% w/w and lubricant at 0.5–1.0% w/w before compression on rotary tablet presses at 10–40 kN. Dissolution testing per USP <711>, content uniformity per USP <905>, and disintegration per USP <701> are used as release criteria; batch size is constrained by granulator bowl capacity, airflow turndown in the dryer, and the ability to maintain bed temperature uniformity within ±3°C during drying. The system must comply with 21 CFR 211.42 for facility design, 21 CFR 211.63 for equipment design, 21 CFR 211.110 for in-process controls and ICH Q3D for elemental impurities. Finished products include immediate-release tablets, orally disintegrating tablets, and capsules prepared from the wet granulated material.

For aqueous injectable formulations, Perlalux Duplex Pharma Grade API is dissolved in Water for Injection at 20–25°C under continuous stirring, with nitrogen blanketing where oxygen sensitivity has been demonstrated in stress studies. The active content is prepared at 0.1% w/v to 10.0% w/v; tonicity is adjusted with sodium chloride or dextrose to 280–320 mOsmol/kg, and pH is controlled within a range selected from solubility and stability curves, typically ±0.2 pH units from the target. The bulk solution is passed through a 0.45 µm prefilter and then through two 0.22 µm sterilising-grade membrane filters in series before aseptic filling into depyrogenated Type I borosilicate glass vials, ampoules or pre-filled syringes under ISO 14644-1:2015 Grade A conditions. Particulate matter is controlled per USP <788>: not more than 6,000 particles per container at ≥10 µm and 600 per container at ≥25 µm for small-volume parenterals, with visible particulates assessed per USP <790>. Sterility assurance follows USP <71>, bacterial endotoxins per USP <85>, and container closure integrity by dye ingress or vacuum decay per USP <1207>. If terminal moist-heat sterilisation at 121°C for 15 min is compatible with the Perlalux chemical stability profile, it is preferred over aseptic processing; otherwise the process is designed under EU GMP Annex 1 aseptic principles with media-fill validation. The manufacturing operation must comply with 21 CFR 211.22 for quality control responsibilities, 21 CFR 211.113 for control of microbiological contamination, 21 CFR 211.165 for testing and release, and ICH Q3D for elemental impurities. Finished product types are aqueous injectable solutions in ampoules, vials and pre-filled syringes for intravenous, intramuscular or subcutaneous administration as defined by the approved marketing authorisation.

When Terminal Sterilisation Cannot Be Applied to Perlalux Injectable Formulations

When terminal sterilisation cannot be applied to Perlalux injectable formulations because of hydrolytic or thermal degradation observed at 121°C, lyophilisation becomes the primary downstream process for long-term stability. Perlalux is dissolved at 2% w/v to 15% w/v in Water for Injection with bulking agents such as mannitol or trehalose at 2–5% w/v and, where necessary, a buffering system. The filtered solution is filled into Type I glass vials with a fill volume of 0.5–2.0 mL in 5–10 mL vials, and partially stoppered before loading onto lyophiliser shelves pre-cooled to −40°C. Freezing is conducted at shelf temperatures between −40°C and −55°C with hold times of 2–4 h; primary drying is executed at chamber pressure 50–150 µbar and shelf temperatures ramped to −10°C to +10°C over 24–72 h; secondary drying at +20°C to +35°C reduces residual moisture to below 1.0% water content measured by USP <921> Karl Fischer titration. Cake appearance and reconstitution time are monitored as in-process attributes; published data for this specific Perlalux lyophilised cake is limited, so reconstitution performance is evaluated during process validation rather than assigned a universal compendial target. Particulate matter complies with USP <788>, sterility with USP <71>, endotoxins with USP <85>, and container closure integrity with USP <1207>. The lyophilisation suite must conform to EU GMP Annex 1 for aseptic processing, ISO 14644-1:2015 for cleanroom classification, and 21 CFR 211.94 for container closure systems. Finished product types are lyophilised powders or cakes for reconstitution in single-dose vials, used where the API cannot be stored as an aqueous solution.